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Summary: Purpose: We reviewed the literature to deter­
mine whether an analysis of published data could clarify 
the relationship between antiepileptic drug (AED) poly­
therapy and adverse affects (AE). We highlight the prob­
lems encountered.
Methods; We made a Medline-search for articles pub­
lished between 1974 and 1994 reporting the number of AE 
and doses or serum levels of every AED, per patient or 
treatment group, and used the PDD/DDD ratio to calculate 
AED load per patient from doses or the OSL/AToxL ratio 
to do so from serum levels of individual drugs. The PDD/ 
DDD is the sum of ratios of the actual prescribed daily 
doses divided by the published average therapeutic dose 
of each drug. The OSL/AToxL is the sum of each observed 
serum level divided by its average toxic level.
Results: We retrieved 118 trial reports. Most had to be 
excluded because of incomplete reporting of concomitant 
medication or AE. The data of the 15 articles selected for 
further analysis indicate a relationship between drug load 
and number of AE. We noted no relationship between the 
number of AEDs administered and AE. In add-on studies,
the difference in neurotoxicity between the active and pla­
cebo arm may be obscured if the relative increase in drug 
load is small, as exemplified by the study of McGuire et 
al. (35).
Conclusions: Articles reporting add-on trials of new 
AEDs generally do not provide detailed information about 
the basic medication to which the new AED is added, 
which makes calculation of total drug load impossible. Fur­
thermore, often only frequency of AE is reported, not 
severity or development of tolerance, making it difficult to 
judge the impact of AE. However, despite the paucity 
of available information, we present some evidence that 
toxicity in AED polytherapy may be related to total drug 
load, rather than to the number of drugs administered. 
Therefore, the present trend to reject polytherapy for fear 
of increased toxicity is not warranted, which removes one 
of the objections to initiating specific research to prove or 
disprove the value of AED combinations as long as the 
drug load is appropriate. Key Words: Polytherapy— 
Antiepileptic drugs—Adverse effects—Drug load— 
Epilepsy.
Antiepileptic drug (A E D ) pharmacotherapy is 
aimed at reducing seizure frequency and severity 
without producing adverse effects (A E). However, 
the reporting of A E  in clinical trials lacks quantitative 
data because A E  are often described in terms of 
frequency and rarely in terms of severity (1). A l­
though the incidence of A E  is important, the degree 
to which they occur also determines the acceptability 
of individual A E D s. W hen quantitative data are pre­
sented, a comparison is complicated because of the 
different rating scales used (2,3).
The risk of developm ent of chronic toxicity has 
been one of the arguments against use of polyphar­
macy in epilepsy (4). Much of this toxicity is believed
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to be directly related to the number of A ED s being 
consumed, as the number of AE is often reduced 
after the number of A E D s is reduced (5,6). Partly for 
this reason, monotherapy has long been advocated by 
leading epileptologists (7).
However, the total A ED  load of a multiple drug 
regimen rather than the number of A E D s may deter­
mine toxicity. High-level duotherapy is more likely 
to be associated with more A E than is the same 
combination of drugs at low serum levels (8). To  
compare the total A E D  load between patients receiv­
ing monotherapy and polytherapy, the prescribed 
daily dose/defined daily dose (P D D /D D D ) ratio and 
the observed serum level/average therapeutic level 
(OSL/ATL) ratio can be used. These are ratios of 
the actual dose or serum level divided by the average 
therapeutic dose or level, respectively. The total drug 
load in polytherapy patients is calculated by summing 
the P D D /D D D s or the OSL/ATLs of the individual 
drugs. Lammers et al. (9) evaluated patients with
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epilepsy using this method combined with a m ethod  
to quantify the incidence and severity of both seizures 
and AE. When the A E D  load of both groups was 
equal, patients receiving polytherapy did not neces­
sarily have higher toxicity than patients receiving 
monotherapy.
Because, the pharmacodynamic action o f seizure 
control does not necessarily correlate with neurotox­
icity, however, the D D D  may not correlate well with 
AE. Instead of the D D D , ideally a defined toxic dose  
should be used in determining drug loads in relation  
to AE. Using serum levels instead of doses has an 
advantage in that average toxic serum levels have 
been published. Instead of the ATL, the average toxic 
level (AToxL) must be substituted in the denom ina­
tor, thus creating an OSL/AToxL ratio. Serum levels, 
contrary to the P D D /D D D  ratio, furthermore reflect 
differences in pharmacokinetics between different 
AEDs, although metabolites and brain concentra­
tions are not accounted for.
In the present study, we surveyed the literature, 
using the P D D /D D D  ratio and the OSL/AToxL ratio 
to evaluate the reporting of AE in relationship to 
AED load. We placed special emphasis on articles 
reporting use of polytherapy in one of the treat­
ment groups.
METHODS
We used the Medline program to screen the litera­
ture from 1974 to 1994, using the search commands 
[epilepsy], [adverse or side effects or cognitive or 
toxicity], and [combination therapy or add-on or dis­
continuation]. Next, we made a further selection us­
ing the following requirements: (a) a multiple A E D  
regimen administered in one of the treatment groups 
of a trial, (b) mention of the dose or serum level of 
every prescribed A E D  per patient or mean dose, 
respectively, serum level, and number of patients 
treated with each A E D  per treatment group; and 
(c) mention of incidence and specification of A E  per 
patient or treatment group.
Total drug load
The D D D  is based on the assumed average daily 
dose in its main indication in adults and is assigned 
by the World Health Organization for each drug. A n  
analogous ratio for A E D  serum levels was developed  
in our institute. AToxL per drug were assessed from  
literature data (10-13). The D D D  and A ToxL were 
determined (Table 1) and were analyzed statistically, 
by Pearson’s correlation coefficient and the z- 
transformation to test correlations between parame­
ters. Dice were thrown to select one observation ran­
domly per patient for statistical analysis.
TABLE 1. DDD and A ToxL values for
individual A E D s














DDD, defined daily dose; AToxL, average toxic level; AEDs, 
antiepileptic drugs.
" Assigned by the World Health Organization. 
b Assigned according to literature data. 
c Nordiazepam level.
RESULTS
Screening of the literature
Through the Medline search, we retrieved 661 arti­
cles, o f which 118 were trial reports with a multiple 
drug regim en in at least one of the treatm ent groups. 
Next, w e applied our requirements to select articles 
suitable for analysis. Three were not suitable because  
two of them  compared differences in frequency of 
administration, e.g., a daily dose versus a three-tim es 
w eekly dose; the third reported a study of a new drug 
for which no information was available about the 
average effective dose. M ost articles were rejected  
for two reasons:
1. Eighty studies in which new drugs, multiple drug 
regimens, or a reduction in the num ber o f A E D s  
in these regimens were evaluated w ere rejected  
because the researchers did not provide data on 
doses or serum levels o f each drug or about the 
num ber of patients treated with the drug; a few  
representative examples are cited (14 -19 ).
2. Twenty papers were rejected because A E  were 
either not mentioned or w ere not adequately  
described. (One fourth of the articles were thus 
deficient). Seizure control was the only outcom e  
m easure in these cases (19-21).
F ifteen papers met the three requirements described  
in the M ethods section. In these, drug toxicity was 
evaluated by listing of subjective com plaints, by re­
peated neurological examinations, and/or by neuro­
psychological testing. Even in these articles, no sys­
tem atic comments were made regarding the severity  
o f the A E . We divided the selected articles into three 
groups: A , B, and C.
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FIG, 1. A: Adverse effects in relation to total drug load in individual patients. Combined data from the studies cited (22-26). From the 
pubiished data, one measurement per patient was taken at random. ^Expressed in prescribed daily dose/defined daily dose. B: Adverse 
effects in relation to number of antiepileptic drugs in individual patients. Combined data from studies cited (22-26). From the published data, 
the same measurement per patient was taken as described in A. Numbered dots indicate number of patients having the sam e coordinates.
A E  and dose/serum levels reported 
p e r  individual patient
la  five articles, the number and dose of all A E D s  
(but not serum levels) and A E  were reported per 
patient (22-26). The total A E D  load in relation to 
the number of A E  in individual patients is shown in 
Fig. 1A. Although the correlation coefficients vary 
between the trials, a weak positive association be­
tween these parameters does exist for the total group 
(r =  0.41). The number o f A E D s in relation to the 
number of A E  is shown in Fig. IB . We did not note 
a significant association between these parameters*
total AED load or a higher OSL/AToxL ratio was 
associated with an increase in A E  (Table 2).
A E  and dose/serum levels reported  
per  treatment group
In seven articles, two treatments were compared 
and the number of A E  effects and the average dose 
or serum level of every A E D  was reported per treat­
ment group (27-33). We calculated the mean total 
A E D  loads or OSL/AToxL ratio per treatment group 
(Table 2) with the respective number of A E reported. 
In all these studies, except that o f Schmidt (27), a 
cross-over design was used. In all the studies, a higher
Drug toxicity evaluated by  
neuropsychological testing
Four articles described neuropsychological testing  
used to detect drug-related changes in cognitive func­
tioning; doses or serum levels were adequately re­
ported (8,33-35). The trial of Wilensky et al. (33) is 
also included in group B.
Different neuropsychological tests were applied by 
the various researchers, which complicated a detailed  
comparison. We calculated the mean total A E D  load  
or OSL/AToxL ratio per treatment group (Table 3). 
The tests the authors used are categorized according  
to cognitive functions and the results of the various  
trials in Table 3. Thus, for example, decision m aking  
and visual scanning are categorized as com ponents  
of mental speed. Intellectual achievement was tested  
by arithmetic in three trials. Patients in treatm ent 
groups with higher drug loads or higher O SL /A T oxL  
ratios performed as well as or worse, but not better,
TABLE 2, Trials in which number o f  adverse effects was reported per treatment group
Reference
Loiseau et al. (28) (n = 23) 
Loiseau et al. (29) (n = 23) 
Tartara et al. (30) (n = 21) 
Sander et al. (31) (n =  18)
Leppik et al. (32) (n =  56) 
Wìlensky et al. (33) (n = 42) 
Schmidt (27) (n =  36)
Treatment groups
VGB versus placebo add-on 
LTG versus placebo add-on 
VGB versus placebo add-on 
LTG versus placebo add-on
Treatment groups
FBM versus placebo add-on 
PB versus CLZ both added to PHT 
Two-drug versus monotherapy
PDD/DDD"
3,6 versus 2.1 
3.1 versus 2.2 




1.7 versus 1.5 
1.4 versus 0.9
No. of side effects
18 versus 11 
50 versus 20 
26 versus 9 
20 versus 14
No, of side effects
133 versus 16 
32 versus 16 
41 versus 31
PDD, prescribed daily dose; OSL, observed serum level; VGB, vigabatrin; LTG, lamotrigine; FBM, felbamate; PB, phénobarbital; PHT, 
phenytoin; CLZ, clorazepate; other abbreviations as in Table 1. 
a Mean total antiepileptic drug load (PDD/DDD) or OSL/ATOxL per treatment group is shown.
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TABLE 3. Trials in which drug-related effects on cognitive functioning were measured
Mental Short-term Attention/ Visuomotor Intellectual Motor
Reference Treatment groups" PDD/DDD* speed memory concentration response level speed
McGuire et al. (35) Adding vigabatrin versus 3.0 versus 2.5 s s s i or s
(n -  30) placebo
Treatment groups" OSL/AToxLft
Duncan et al. (34) After removal of PHT 1.2 versus 0.9 s s
1l s fl
(n -  23) from a multiple drug
regimen
Duncan et al. (34) After removal of CBZ 0.9 versus 0.4 s s s s 41
(n = 24) from a multiple drug
regimen
Duncan et al. (34) After removal of VPA 0.9 versus 0.6 s s s s
«l
(n = 25) from a multiple drug
regimen
Wilensky et al. (33) PB instead of CLZ in 1.7 versus 1,5 d s s
(n = 42) combination with PHT
Thompson and A change from high-level 0.95 versus 0.63 ¥i
*1 *l s
Trimble (8) to low-level multiple
(n = 28) drug regimens
CBZ, carbamazepine; VP A, valproate; d, deteriorated; i, improved; s, same; other abbreviations as in Tables 1 and 2.
Trial designs, total drug loads and conclusions regarding cognitive changes as described in different reports. The changes in the cognitive 
functions are those observed after the second treatment was substituted for the first (i.e., VGB vs. placebo-the condition while receiving 
placebo).
° Characterization of groups: In trials by Wilensky et al. (28), Duncan et al. (30), and Thompson and Trimble (5), a cross-over design was 
used. In the trial by McGuire et al. (31), a parallel design was used.
b Total antiepileptic drug-load (in PDD/DDD) or OSLA/AToxL is shown per treatment group.
on neuropsychological tests than patients in treat­
ment groups with a lower drug load.
DISCUSSION
Critique of the literature
Methods of assessing AE, and in particular m eth­
ods of reporting about the incidence, leave much to 
be desired. Very few of the article we collected in 
this literature search satisfied the requirements for 
inclusion. Lack of information about the exact dos­
ages or serum levels of individual A ED s, or about 
the frequency of AE, or both, was particularly fre­
quent. The few articles selected would have been  
reduced even further if adequate quantification of 
the severity of A E  had been a requirement. This 
further compromises the comparability o f trials with 
regard to toxicity, because, if no use is made of vali­
dated scales, it is debatable whether one can weigh  
the impact of AE if 10% of patients in one group and 
20% in another group report dizziness. It is equally 
unclear how one can compare five cases of nausea 
in one group with five cases of drowsiness in another 
group without measuring how the health-related 
quality of life is affected. Several rating lists for scor­
ing A E quantitatively according to type and severity 
are now in use or are being developed (2,3). These 
lists will provide individual toxicity scores by which 
patients can be compared. Such potential extra infor­
mation may be undermined by the use of different
tests in trials. This point is clearly evident when the 
articles used in this study are compared.
Relation between number of AEDs, total drug 
load, and AE
Only group A  articles allowed comparison of toxic­
ity in individual patients and could therefore be used 
to estim ate the correlation coefficient between toxic­
ity and drug load, respectively, and number of 
A E D s administered.
Comparison of the articles in group A shows that 
the correlation between incidence of AE and drug 
load is slightly stronger than that between AE and 
number o f A E D s received, although both are weak 
and thus cannot be taken as proof. An inherent weak­
ness of our analysis is that D D D  are established only 
for the main indication of a drug, i.e., seizure control, 
and not for toxicity. Although correlations between 
serum levels and toxicity have been published, few  
articles retrieved in our study contained information 
about serum levels. This is regretable because the 
P D D /D D D  ratio does not account for possible phar­
m acokinetic interactions. In group B and C articles, 
we could not disentangle the cause of greater toxicity, 
which might just as well be due to the higher drug 
load as to use of multiple A ED s or to both. Although 
the information we report does not yet permit conclu­
sions regarding the superiority of polytherapy to mo­
notherapy, it does remove one of the objections
Epilepsia, Vol. 38, No. 5, 1997
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against renewing the study of relative efficacy of 
mono- and polytherapy, keeping the considerations 
of equal drug load in mind. That polytherapy may 
have its merits has been advocated, e.g., in hyperten­
sion and oncology therapy (36-38). A  prospective 
randomized double-blind study is in progress to ver­
ify the advantages or disadvantages of polytherapy 
in the treatment of epilepsy.
Not all the results we obtained were in accordance 
with the hypothesis of an association between total 
drug load and number of AE. One study in group 
C showed that elimination of phenytoin did have 
a beneficial effect on attention and concentration, 
whereas discontinuation of valproate or carbamazep- 
ine did not (34). This finding is in accord with reports 
that different A E D s often have different effects on 
cognitive functioning (39,40). Barbiturates have a 
greater impact on mental speed than do phenytoin, 
carbamazepine, and valproate (41). These differing 
drug effects emphasize the need for information 
about the quality of toxicity and its relationship to 
dosages. Qualitative and quantitative knowledge of 
drug-related toxicity is essential for accurate insight 
into the potential therapeutic window and the conse­
quent merits of a drug. Using drug loads in relation­
ship to dosages allows comparison of single and/or 
multiple drug regimens and thus provides a better 
tool for interpretation and evaluation of differences 
in seizure control or toxicity. Having knowledge of 
both therapeutic and toxic serum levels, instead of 
dosages in evaluations of patients with difficult-to- 
treat epilepsy receiving multiple drug regimens 
allows one to becom e cognizant of individual differ­
ences in metabolism. The use of serum levels does 
increase the cost of therapeutic drug monitoring, 
however.
The advantages of using methods to calculate total 
A E D  load are illustrated by the study of McGuire 
et al. (35), in which total drug loads in the vigabatrin 
add-on group and the placebo control group were 
high. Adding vigabatrin changed the drug load only 
by 20%. Therefore, given the premises of this method 
calculating total drug load, the patients in the placebo 
group were exposed to only a slightly less toxic total 
drug load than that of the add-on group, from which 
the effect of vigabatrin on cognitive function had 
to be evaluated. This emphasizes the importance of 
reporting doses or serum levels of concomitantly ad­
ministered drugs, particularly in parallel studies.
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